14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.72 $7.24 Wednesday, 24th Apr 2024 AFMD stock ended at $4.88. This is 8.79% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 11.72% from a day low at $4.87 to a day high of $5.44.
90 days $4.25 $7.24
52 weeks $2.24 $11.10

Historical Affimed N.V. prices

Date Open High Low Close Volume
Feb 18, 2021 $61.50 $62.50 $60.15 $61.40 91 796
Feb 17, 2021 $61.20 $62.90 $59.80 $62.50 154 732
Feb 16, 2021 $60.90 $62.75 $60.20 $61.80 89 997
Feb 12, 2021 $61.10 $62.80 $59.80 $60.90 72 353
Feb 11, 2021 $60.80 $62.10 $59.60 $61.10 114 352
Feb 10, 2021 $62.60 $63.70 $59.20 $60.00 163 537
Feb 09, 2021 $62.50 $64.60 $60.60 $62.30 189 089
Feb 08, 2021 $59.90 $62.00 $59.20 $60.00 110 885
Feb 05, 2021 $57.60 $59.60 $56.85 $59.45 144 057
Feb 04, 2021 $61.70 $62.30 $56.50 $57.40 240 410
Feb 03, 2021 $61.00 $64.90 $57.50 $60.60 220 149
Feb 02, 2021 $57.60 $60.20 $57.00 $58.75 199 048
Feb 01, 2021 $58.40 $59.60 $56.50 $57.40 176 093
Jan 29, 2021 $58.40 $60.20 $55.60 $57.30 183 565
Jan 28, 2021 $57.80 $60.28 $57.10 $58.60 132 282
Jan 27, 2021 $59.60 $59.60 $55.40 $57.20 263 655
Jan 26, 2021 $65.60 $65.90 $60.00 $60.30 198 274
Jan 25, 2021 $65.70 $66.00 $61.20 $65.60 132 967
Jan 22, 2021 $65.00 $65.90 $62.33 $65.20 153 504
Jan 21, 2021 $69.80 $70.00 $64.60 $65.80 158 534
Jan 20, 2021 $69.60 $70.50 $66.10 $69.70 209 873
Jan 19, 2021 $70.04 $71.80 $67.20 $69.50 184 138
Jan 15, 2021 $70.70 $70.90 $65.10 $68.80 269 044
Jan 14, 2021 $72.52 $72.52 $68.30 $70.30 265 667
Jan 13, 2021 $66.10 $74.80 $64.90 $72.00 783 403
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT